07:00 , Apr 10, 2006 |  BC Week In Review  |  Company News

Angiogen, Microbix deal

MBX received exclusive worldwide rights to commercialize Angiogen's Angiostatic Cocktail, which is in Phase I testing for cancer. The product contains urokinase and an undisclosed small molecule. MBX will manufacture and supply urokinase, and the...
07:00 , Oct 10, 2005 |  BC Week In Review  |  Clinical News

TPA/mesna: Phase I data

Data from a dose-escalation Phase I trial in 15 patients showed that tPA/mesna decreased tumor markers in 2 patients in the 5 mg/hr tPA cohort, but no clinical objective responses were seen. Angiogen said that...
08:00 , Nov 25, 2002 |  BC Week In Review  |  Clinical News

BioBypass angiogen: Phase II

In the North American Phase II REVASC trial in 71 patients with severe coronary artery disease, BioBypass significantly improved ST segment depression, the primary endpoint, at 6 months compared to standard of care (p=0.024). However,...
08:00 , Nov 25, 2002 |  BioCentury  |  Finance

AHA movers

AHA movers Company Product Key data 11/22 cls Wk chg % chg Mkt cap chg 11/22 mkt cap Alexion (ALXN) Pexelizumab C5 complement inhibitor Significant reduction in secondary endpoint of 90-day mortality in one of...
08:00 , Nov 25, 2002 |  BioCentury  |  Product Development

Telik's sensitive situation

With maturing Phase II cancer data in hand for its TLK286 , Telik Inc. is preparing to start Phase III trials in advanced ovarian cancer in the first quarter next year. The company believes that...
08:00 , Nov 20, 2002 |  BC Extra  |  Clinical News

GenVec Phase II cardiovascular results

GNVC said in the North American Phase II REVASC trial in 71 patients with severe coronary artery disease, its BioBypass angiogen significantly improved ST segment depression, the primary endpoint, at six months compared to standard...
07:00 , Aug 19, 2002 |  BC Week In Review  |  Company News

Crucell, GenVec deal

GNVC received a non-exclusive worldwide license from CRXL to use the PER.C6 cell line in the development of GNVC's lead cardiovascular product candidate BioBypass angiogen. CRXL will receive an upfront fee, annual payments and royalties....
07:00 , Jul 15, 2002 |  BC Week In Review  |  Company News

BioReliance, GenVec Inc deal

BREL will provide for GNVC 100 liter scale manufacturing services and related testing for GNVC's BioBypass angiogen and TNFerade adenoviral vector. BioBypass is in Phase II testing for coronary artery and peripheral vascular disease, and...
07:00 , May 1, 2002 |  BC Extra  |  Clinical News

GenVec completes Phase II CAD enrollment

GNVC completed enrollment in a U.S. Phase II trial comparing its BioBypass angiogen against standard therapy in 71 patients with severe coronary artery disease. The primary endpoint is changes in exercise treadmill time (ETT), and...
08:00 , Jan 29, 2001 |  BC Week In Review  |  Company News

GenVec, Pfizer deal

The companies will terminate their deal for preclinical research on angiogenesis in July 2001, a year earlier than originally agreed in 1997 (see BioCentury, Sept. 15, 1997). GNVC received $30 million of the $34 million...